1119 related articles for article (PubMed ID: 24342619)
1. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
[TBL] [Abstract][Full Text] [Related]
3. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Bianchi R; Cervellini I; Porretta-Serapiglia C; Oggioni N; Burkey B; Ghezzi P; Cavaletti G; Lauria G
J Pharmacol Exp Ther; 2012 Jan; 340(1):64-72. PubMed ID: 21984837
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
7. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
[TBL] [Abstract][Full Text] [Related]
8. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S; Sole S
Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
Higashijima Y; Tanaka T; Yamaguchi J; Tanaka S; Nangaku M
Am J Physiol Renal Physiol; 2015 Apr; 308(8):F878-87. PubMed ID: 25656369
[TBL] [Abstract][Full Text] [Related]
10. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Jin HY; Liu WJ; Park JH; Baek HS; Park TS
Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
12. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.
Terasaki M; Nagashima M; Watanabe T; Nohtomi K; Mori Y; Miyazaki A; Hirano T
Metabolism; 2012 Jul; 61(7):974-7. PubMed ID: 22225957
[TBL] [Abstract][Full Text] [Related]
13. Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy.
He J; Yuan G; Cheng F; Zhang J; Guo X
Metab Syndr Relat Disord; 2017 Sep; 15(7):344-353. PubMed ID: 28737448
[TBL] [Abstract][Full Text] [Related]
14. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
Ohga S; Shikata K; Yozai K; Okada S; Ogawa D; Usui H; Wada J; Shikata Y; Makino H
Am J Physiol Renal Physiol; 2007 Apr; 292(4):F1141-50. PubMed ID: 17190910
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
Chinda K; Palee S; Surinkaew S; Phornphutkul M; Chattipakorn S; Chattipakorn N
Int J Cardiol; 2013 Jul; 167(2):451-7. PubMed ID: 22285447
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
20. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Tian L; Gao J; Hao J; Zhang Y; Yi H; O'Brien TD; Sorenson R; Luo J; Guo Z
Endocrinology; 2010 Jul; 151(7):3049-60. PubMed ID: 20444936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]